Page 70 - Depression in adults: treatment and management
P. 70

Depression in adults: treatment and management (NG222)



                   •  discussing the risks and benefits with the person or, if appropriate, their advocate or

                      carer. [2022] [2022]

         1.13.6  Clinics should only provide ECT if they:



                   •  are Electroconvulsive Therapy Accreditation Service (ECTAS) accredited


                   •  provide ECT services in accordance with ECTAS standards

                   •  submit data, including outcomes, on each course of acute and maintenance ECT they

                      deliver as needed for the ECTAS minimum dataset.


                      Follow the ECT Accreditation Service Standards for Administering ECT. [2022] [2022]


         1.13.7  Trusts which provide ECT services should ensure compliance with the ECTAS
                 standards for administering ECT through board-level performance
                 management. [2022] [2022]



         1.13.8  Stop ECT treatment for a person with depression:


                   •  immediately, if the side effects outweigh the potential benefits, or or


                   •  when stable remission has been achieved. [2022] [2022]


         1.13.9  If a person's depression has responded to a course of ECT:


                   •  start (or continue) antidepressant medication or a psychological intervention to

                      prevent relapse and to provide ongoing care for their depression (see the
                      recommendations on preventing relapse)


                   •  consider lithium augmentation of antidepressant medication (see the
                      recommendations on further-line treatment). [2022] [2022]



            For a short explanation of why the committee made these recommendations and how they
            might affect practice, see the rationale and impact section on further-line treatment.



            Full details of the evidence and the committee's discussion are in evidence review D: further-
            line treatment.









         © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-  Page 70 of
         conditions#notice-of-rights).                                                                       103
   65   66   67   68   69   70   71   72   73   74   75